TargetGene Biotechnologies

About

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is TargetGene Biotechnologies' primary focus in biotechnology?

TargetGene Biotechnologies focuses on developing efficient and highly specific DNA editing solutions for living organisms, particularly for human gene therapy with an emphasis on inherited diseases and cell-based immunotherapy.

When was TargetGene Biotechnologies founded and where is it headquartered?

TargetGene Biotechnologies was founded in October 2012 and is headquartered in Rehovot, Israel.

What is the name of TargetGene Biotechnologies' patented gene editing platform?

TargetGene Biotechnologies' patented and patent-pending gene editing platform is called TGEE (genome editing engine), which has developed RNA-guided gene targeting.

How much funding has TargetGene Biotechnologies raised in total?

TargetGene Biotechnologies has raised a total of $9,200,000 in funding. For a full financing history, please refer to startupim.

What is TargetGene Biotechnologies' current funding stage?

TargetGene Biotechnologies is currently in its Series B funding stage.

What was a significant partnership for TargetGene Biotechnologies in June 2016?

In June 2016, TargetGene Biotechnologies inked gene editing technology licensing deals with Monsanto and Nomad Bioscience.

What was the subject of an interview with TargetGene Biotechnologies' CEO in December 2019?

In December 2019, Yoel Shiboleth, CEO of TargetGene Biotechnologies, was interviewed about the TGEE platform as a potential replacement for CRISPR in gene editing.

How many employees does TargetGene Biotechnologies currently have?

TargetGene Biotechnologies currently has 7 employees.

Sectors & technology

Highlights

Tags